WASHINGTON, Jan. 6 -- IQVIA, a prominent global provider of advanced analytics and clinical research services, has submitted a public comment letter to the U.S. Food and Drug Administration addressing the agency's draft guidance on postapproval methods to capture safety and efficacy data for cell and gene therapy products. In its letter, IQVIA expressed appreciation for the opportunity to share insights on the recently released guidance, asserting that comprehensive feedback is essential for ref more ST